The overall aims of this Prostate Cancer Advocate Core are to a) engage researchers and advocatesin dialogue that will contribute patient insights to the research programs of the SPORE and b) to provideinformation about prostate cancer and prostate cancer research to patients and the community. This is anewly established core.Specifically, this will involve advocates in discussion with researchers about the benefits andrelevance of their research to patients and on the contribution that will result from a successful completion oftheir work. The advocates will participate in clinical trial protocol development and consent form reviews forSPORE projects to provide the viewpoint of the patient and enhance the comprehensibility and acceptabilityof the documents. The advocates will assist in accrual for clinical trials. They will also participate inresearch proposal reviews to provide a patient/consumer point-of-view.The community-based aim will focus on persons who have been diagnosed with prostate cancer,their supporting family members, at-risk familial extensions of the patient, and members-at-large of thecommunity. There is both a lack of knowledge and misinformation about prostate cancer among thesepersons. The work of the advocates will include going into the community to provide information aboutprostate cancer and its detection and treatment, while providing information about SPORE research andclinical trials, and providing patients and their families with a broad program of education through theestablished support group. This work is intended to encourage early screening testing, demonstrate accessto information resources, and increase awareness of treatment options and clinical trials. This kind ofinformation can contribute directly to earlier diagnosis and treatment and to a higher rate of successfuloutcomes and patient satisfaction. Mayo Prostate SPORE advocates are now significantly involved withprostate advocates from other Prostate SPOREs and with advocates from other Mayo SPOREs. Theprostate advocates also participate with other organizations related to the Mayo Comprehensive CancerCenter. The interests of present and especially those of future prostate cancer patients will be enhanced bythe addition of this core to the Mayo Prostate SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091956-08
Application #
7729583
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-09-11
Project End
2011-08-31
Budget Start
2008-09-11
Budget End
2009-08-31
Support Year
8
Fiscal Year
2008
Total Cost
$1,900
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Ahmed, Kamran A; Davis, Brian J; Mynderse, Lance A et al. (2014) Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol 9:171
Wu, Qiang; Kohli, Manish; Bergen 3rd, H Robert et al. (2014) Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth. Mol Cancer Ther 13:1067-77

Showing the most recent 10 out of 206 publications